A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

NCT04044222 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Classic Hodgkin's Lymphoma

Interventions

BIOLOGICAL: Sintilimab
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Ifosfamide
DRUG: Placebo
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Ifosfamide

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.